New england journal of medicine publishes data from ecospor lll phase 3 study evaluating investigational microbiome therapeutic ser-109 in recurrent c. difficile infection

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced the publication in the new england journal of medicine (nejm) of data from its phase 3 ecospor iii study evaluating ser-109, an investigational oral microbiome therapeutic for the treatment of recurrent c. difficile infection (rcdi). the publication highlights data that found ser-109 to be superior to placebo in reducing cdi recurrence, with 88% of ser-109 patie
MCRB Ratings Summary
MCRB Quant Ranking